ALK and meningioma: These combinations in meningioma cells included: cabozantinib (an inhibitor of RTKs, including vascular endothelial growth factor receptor 2 [VEGFR2] and hepatocyte growth factor receptor MET)/danusertib (an Aurora kinase inhibitor), dasatinib (an inhibitor of BCR-ABL and SRC-family TKs)/GSK2126458 (a dual PI3K/mTOR inhibitor), and MK-2206 (an AKT inhibitor)/ALK-IN-1 (an inhibitor of ALK and multiple other TKs) (Fig 2A).